secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001193125-25-178970
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero reports Q2 results and tebipenem Phase 3 success; plans FDA filing in 2H 2025
--------------------------------------------------------------------------------

- Q2 2025 net loss $1.7M ($0.03/share) vs $17.9M ($0.33) in Q2 2024; revenue $14.2M up from $10.2M.
- Phase 3 PIVOT-PO trial of tebipenem HBr in cUTI met primary endpoint; IDMC stopped early for efficacy.
- Spero and GSK plan to submit data to FDA in 2H 2025; potential milestone payments adjusted to up to $101M from $150M.
- Cash $31.2M at June 30 plus $23.8M GSK milestone received Aug 2025; runway expected into 2028.
- Esther Rajavelu appointed CEO/President effective May 2, 2025, continuing as CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312525178970/0001193125-25-178970-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312525178970/d97572d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-178970

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer